Trial Outcomes & Findings for Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents (NCT NCT00140842)

NCT ID: NCT00140842

Last Updated: 2021-11-02

Results Overview

Peak growth hormone (GH) on the GH stimulation test is a measure of the adequacy of GH secretion.

Recruitment status

COMPLETED

Target enrollment

47 participants

Primary outcome timeframe

Baseline

Results posted on

2021-11-02

Participant Flow

17 obese and 30 normal-weight adolescents (12-18 yr old) were screened for study eligibility.15 obese adolescents completed the study visit. These subjects were matched for race, ethnicity, and bone age to normal-weight adolescents from the pool of screened subjects.

Participant milestones

Participant milestones
Measure
Normal-weight Girls
Normal weight girls 12-18 years old
Obese Girls
Obese adolescents between 12-18 years old.
Overall Study
STARTED
15
15
Overall Study
COMPLETED
15
15
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Neuroendocrine Modulation of Metabolic Effects in Overweight Adolescents

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Normal-weight Girls
n=15 Participants
Normal-weight girls were required to have a BMI between the 15th-85th percentiles
Obese Girls
n=15 Participants
Obese girls were required to have a BMI above the 95th percentile
Total
n=30 Participants
Total of all reporting groups
Age, Categorical
<=18 years
15 Participants
n=5 Participants
15 Participants
n=7 Participants
30 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Continuous
15.9 years
STANDARD_DEVIATION 1.7 • n=5 Participants
14.0 years
STANDARD_DEVIATION 1.9 • n=7 Participants
14.9 years
STANDARD_DEVIATION 3.3 • n=5 Participants
Sex: Female, Male
Female
15 Participants
n=5 Participants
15 Participants
n=7 Participants
30 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline

Population: This was a cross-sectional study to compare differences in growth hormone (GH) secretory status in relation to body composition in obese versus normal-weight girls. This was a pilot study and the analysis was performed using a Student t-test to compare means across groups

Peak growth hormone (GH) on the GH stimulation test is a measure of the adequacy of GH secretion.

Outcome measures

Outcome measures
Measure
Normal-weight Girls
n=15 Participants
Normal-weight girls were required to have a BMI between the 15th-85th percentiles
Obese Girls
n=15 Participants
Obese girls were required to have a BMI above the 95th percentile
Peak Growth Hormone (GH) on the GH Stimulation Test
40.1 ng/ml
Standard Deviation 16.1 • Interval 0.0 to 100.0
25.2 ng/ml
Standard Deviation 21.8

SECONDARY outcome

Timeframe: Baseline

Population: The analysis was completed on the 30 participants as per protocol

Visceral adipose tissue was measured using magnetic resonance imaging at the level of the fourth lumbar vertebra (L4)

Outcome measures

Outcome measures
Measure
Normal-weight Girls
n=15 Participants
Normal-weight girls were required to have a BMI between the 15th-85th percentiles
Obese Girls
n=15 Participants
Obese girls were required to have a BMI above the 95th percentile
Visceral Adipose Tissue
19 grams
Standard Deviation 7.5 • Interval 0.0 to 100.0
42.7 grams
Standard Deviation 17.0 • Interval 0.0 to 100.0

Adverse Events

Normal-weight Girls

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Obese Girls

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Madhu Misra, MD

Massachusetts General Hospital

Phone: 617-724-5602

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place